 Connection
Samuel Dominguez to Infliximab
This is a "connection" page, showing publications Samuel Dominguez has written about Infliximab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.533 |
|
|
|
-
Dominguez SR, Birkholz M, Anderson MS, Heizer H, Jone PN, Glode MP, Todd JK. Diagnostic and Treatment Trends in Children With Kawasaki Disease in the United States, 2006-2015. Pediatr Infect Dis J. 2019 10; 38(10):1010-1014.
Score: 0.658
-
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glod? MP, Dominguez SR. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective? Pediatr Infect Dis J. 2018 10; 37(10):976-980.
Score: 0.614
-
Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
Score: 0.158
-
Dominguez SR, Anderson MS. Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013 Feb; 25(1):103-9.
Score: 0.104
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|